

**S3 Table.** Clinical Outline, Treatment summary, and karyotype summary

Demographics	African-American	Caucasian	p-value (Fisher's)
<b>GENDER</b>			
Male	59.8% (76/127)	62.4% (369/591)	0.585
Female	40.1% (51/127)	37.5% (222/591)	0.585
<b>AGE(years)</b>			
25-39	3.1% (4/127)	1.7% (10/591)	0.282
40-49	11% (14/127)	4.6% (27/591)	0.004
50-59	21.3% (27/127)	24.5% (145/591)	0.433
60-69	38.6% (49/127)	37.9% (224/591)	0.886
70-79	14.2% (118/127)	22.3% (132/591)	0.040
80-89	11% (14/127)	8.1% (48/591)	0.291
90-99	0.8% (1/127)	0.8% (5/591)	0.948
<b>Treatment</b>			
IMiDs	6.3% (8/127)	5.4% (32/591)	0.694
Carfilzomib	1.6% (2/127)	1.7% (10/591)	0.926
Bortezomib	25.2% (32/127)	28.4% (168/591)	0.462
Bortezomib/IMiDs	57.5% (73/127)	56.5% (334/591)	0.842
Carfilzomib/IMiDs	5.5% (7/127)	4.9% (29/591)	0.777
Carfilzomib/Bortezomib	0.7% (1/127)	0.5% (3/591)	0.701
Carfilzomib/IMiDs/Bortezomib	3.1% (4/127)	2.5% (15/591)	0.697
<b>Karyotype</b>			
Hyperdiploid	53.5% (68/127)	55.8% (303/591)	0.642
Nonhyperdiploid	46.4% (59/127)	48.7% (288/591)	0.642